How has been the historical performance of SMS Pharma.?

Answer:The historical performance of SMS Pharma shows a significant upward trend in net sales and profitability over the years, particularly from March 2023 to March 2025.

Breakdown:
SMS Pharma's net sales increased from 522.05 Cr in March 2023 to 782.75 Cr in March 2025, indicating strong growth. The total operating income followed a similar trajectory, rising from 522.05 Cr in March 2023 to 782.75 Cr in March 2025. The raw material cost also increased, reaching 501.87 Cr in March 2025, while total expenditure rose to 643.75 Cr in the same period. Operating profit, excluding other income, improved from 54.48 Cr in March 2023 to 139.00 Cr in March 2025, reflecting enhanced operational efficiency. Profit before tax surged from 5.35 Cr in March 2023 to 92.34 Cr in March 2025, and profit after tax rose from 3.88 Cr to 67.40 Cr during the same timeframe. The consolidated net profit showed a recovery from a loss of -7.06 Cr in March 2023 to a profit of 69.14 Cr in March 2025. Additionally, the company's total assets increased from 879.61 Cr in March 2023 to 1,034.09 Cr in March 2024, while total liabilities also grew from 879.61 Cr to 1,034.09 Cr. Cash flow from operating activities improved significantly, reaching 50.00 Cr in March 2024, compared to 22.00 Cr in March 2023. Overall, SMS Pharma demonstrated robust growth in sales and profitability, alongside a healthy cash flow position.